Rochester Mayor Presents DMC’s $6 Billion Investment Plan in Shanghai — BioTech Ignites a New Engine for U.S.–China Health Collaboration!

SaniMed
Nov 3, 2025
3 min read

On November 2, 2025, the U.S.–China Forum on Health Innovation and Collaboration was successfully held at Zhangjiang Hi-Tech Park, Shanghai, jointly hosted by the U.S.

Heartland China Association (USHCA) and the Lin-gang Medical Device Innovation Center, organized by BioTech (Shanghai), and guided by the Shanghai Center of Biomedicine Development.

The forum gathered government officials, researchers, MedTech innovators, and investors from both China and the United States to discuss cross-border innovation, capital cooperation, and globalization strategies in healthcare. Conducted in a closed-door roundtable format, it aimed to promote tangible partnerships and industrial collaboration.

🏛 Forum Overview

Date: November 2, 2025 (Sunday)

Venue: Conference Room, 199 Guoshoujing Road, Zhangjiang Hi-Tech Park, Shanghai

The forum opened at 9 a.m. with welcoming remarks by Liu Houjia, Director of the Shanghai Center of Biomedicine Development, and Min Fan, Executive Director of USHCA. Both speakers emphasized the complementary strengths and cooperation potential of China and the U.S. in health technology innovation in the post-pandemic era.

🌐 Global Vision: The Rochester DMC Case

Kim Norton, Mayor of Rochester, Minnesota, delivered a keynote titled“Rochester DMC – A Global Destination for Health: Mayo Clinic as an International Innovation Engine.”

She highlighted the evolution of Destination Medical Center (DMC)—the largest economic development initiative in Minnesota’s history, with a total investment exceeding US $6 billion—and its mission to make Rochester the world’s premier hub for health and life-science innovation.

Mayor Norton traced the Mayo Clinic’s 140-year legacy, from its founding after the 1883 tornado through its present scale of 2,000 beds, 40,000 employees, and patients from 130+ countries, investing over US $450 million annually in research.Under its strategy “Bold. Forward. Unbound.”, DMC is integrating physical and digital innovation spaces to build a healthcare ecosystem focused on Cure – Connect – Transform. Its Discovery Square Innovation District, just 495 steps from Mayo Clinic, hosts laboratories, GMP facilities, and 3D-printing centers for collaboration between scientists and clinicians.

The Soft Landing Program offers international enterprises regulatory, financial, and market-entry support—providing a gateway for Chinese innovators to establish a presence in the U.S.

💡 New Global Opportunities for Chinese Enterprises

Jim Wu (M.D., MBA), Chairman of BioTech (Shanghai) and Founder of SaniMed Science Group, delivered a keynote titled“Opportunities for U.S.–China Health Industry Collaboration and Global Expansion Strategies.”

Drawing on three decades of cross-border investment and industry experience, Dr. Wu outlined three main globalization paths for Chinese MedTech and biopharma companies:

1️⃣ NewCo Model – Establishing new U.S. entities for FDA registration.

2️⃣ Partnership Model – Entering through licensing, JV, or M&A.

3️⃣ Brand Globalization – Building international reputation via conferences and media.

He emphasized that AI is transforming the global go-to-market process, connecting R&D, registration, clinical adoption, and commercialization through predictive analytics and KOL network mapping.

🤝 Industry Collaboration & Risk Management

Prof. Tang Jun (Shanghai Center of Biomedicine Development) presented the latest progress in Shanghai’s life-science ecosystem, highlighting Zhangjiang and Lin-gang as leading international innovation hubs.

Tian Ruixue, Executive Director of the Lin-gang MDIC, shared China’s experiences in supporting device companies’ globalization through policy and service platforms.

Cao Yanyue from Ping An Property Insurance Shanghai discussed overseas project risk management and insurance mechanisms to ensure secure international operations.

🧭 BioTech & SaniMed’s Role and Outcomes

As the organizer and key speaker, BioTech (Shanghai) not only coordinated the forum but also facilitated cross-border dialogue between Chinese and U.S. health-tech ecosystems. Its U.S. partner, SaniMed Science Group, provided insights on AI-driven commercialization and global innovation trends.

Jim Wu shared actionable strategies drawn from real-world cross-border projects, and during the roundtable, he joined representatives from DMC, Lin-gang, and Ping An Insurance to discuss practical cases of U.S.–China collaborative innovation and corporate globalization, receiving enthusiastic responses from attending companies.

🌟 Forum Summary

The U.S.–China Forum on Health Innovation and Collaboration served as both a high-level dialogue and a practical cooperation platform, deepening discussions on medical technology, international registration, investment, and market access.

Through this event, BioTech (Shanghai) and SaniMed Science Group demonstrated their professional strength in global MedTech innovation and market-entry consulting. Multiple Chinese and U.S. companies expressed interest in further cooperation in FDA registration guidance, international compliance consulting, and AI-enabled market expansion.

The successful conclusion of the forum marks a new phase of open, win-win collaboration between the Chinese and American healthcare industries—proving once again that “Innovation knows no borders; collaboration creates the future.”